[June 10, 2016]

Global Gastric Cancer Market Report: 2016 Edition - Low Penetration of New Targeted Therapies & Lack of Reimbursement of Cancer Drugs - Research and Markets

Research and Markets has announced the addition of the "Global Gastric Cancer Market Report: 2016 Edition" report to their offering.

The report provides an overview of the entire market through global and regional analysis. Prevalence and market value of gastric cancer across the globe and that of its various types and stages including advanced, her2 positive, stage III and metastatic gastric cancer have been analyzed.

The causes of stomach cancer are rather unclear in medical study; however, there is a strong correlation between a diet high in smoked, salted and pickled foods, obesity and ageing. People with Helicobacter infections are also highly prone to gastric cancer. Symptoms of gastric cancer may include, fatigue, feeling bloated after eating, severe heartburn and indigestion, stomach pain, persistent and unexplained vomiting and nausea, unintentional weight loss, belching, anemia, and persistent ulcer. Its medical diagnosis techniques involve upper endoscopy, imaging tests and exploratory surgery. Treatment options include surgery, chemotherapy, radiotherapy and targeted therapy.

Global gastric cancer maret is conspicuous by poor prognosis, because of the indolent nature of the disease. However, better diagnostic technology and shifting treatment market from chemotherapy to targeted therapies is expected to warrant positive growth in the years ahead. Rising oncology drug spending, ageing population, increasing obese population and rising global male population are expected to drive this growth. Certain trends in the global gastric cancer market include, a healthy pipeline of combinations targeted therapies, shifting focus towards molecular targeted therapies, and keen interest in eradication H. Pylori infection across the globe. The market is however, afflicted by certain challenges like low penetration of new targeted therapies and lack of reimbursement of cancer drugs.

Market Dynamics

• Growth Drivers
• - Rising Spending on Targeted Cancer Therapies
• - Rising Oncology Drug Spending
• - Rising Ageing Population
• - Increasing Obese Population
• - Rising Global Male Population
• - Rising Cigarette Consumption
• Trends
• - Combinations Targeted Therapies under Development
• - Targeted Agents in Development by Pathways
• - Shifting Focus towards Molecular Targeted Therapies
• - H. Pylori Eradication
• Challenges
• - Low Penetration of New Targeted Therapies
• - Lack of Reimbursement of Cancer Drugs

Key Topics Covered:

1. Market Overview

2. Global Market

3. Regional Markets

4. Market Dynamics

5. Competitive Landscape

6. Company Profiles

- AstraZeneca Plc.

- Bristol Myers Squibb

- Merck & Co. Inc.

- Roche Holdings AG

For more information visit http://www.researchandmarkets.com/research/rmpb2z/global_gastric

View source version on businesswire.com: http://www.businesswire.com/news/home/20160610005230/en/

[ Back To TMCnet.com's Homepage ]